Treatment targeting PI3K may delay resistance to anti-HER2 therapy in breast cancer patients

(American Association for Cancer Research) Early use of PI3K inhibitors may prevent or delay treatment resistance. Cancer cells resistant to anti-HER2 therapy had high levels of survivin. Newly identified biomarker may help predict anti-HER2 therapy resistance.

Source: EurekAlert! - Medicine and Health - January 23, 2013 Category: Global & Universal Source Type: news